Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Thromb Haemost. 2011 Mar;9(3):531–539. doi: 10.1111/j.1538-7836.2010.04167.x

Fig. 3.

Fig. 3

Inhibition of FVIIa-TF proteolytic activity by PAI-1. (A) FVIIa (10 nM) and relipidated TF (50 nM) were incubated with varying concentrations of PAI-1 in the absence (○) or presence of vitronectin (1 μM) (●) or heparin (10 U/ml) (▲) for 1 h. At the end 1 h, residual FVIIa-TF proteolytic activity was measured in FX activation assay as described in Materials and Methods. (B) FVIIa (10 nM) and relipidated TF (50 nM) were incubated for varying times with PAI-1 (1 μM) in the absence (○) or presence of vitronectin (1 μM) (●) or heparin (10 U/ml) (▲) and the residual FVIIa-TF activity was measured in FX activation assay. Data shown in the figure represent the mean ± SEM (n = 3).